Engineered lentivector targeting of dendritic cells for in vivo immunization
- 24 February 2008
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 26 (3) , 326-334
- https://doi.org/10.1038/nbt1390
Abstract
We report a method of inducing antigen production in dendritic cells by in vivo targeting with lentiviral vectors that specifically bind to the dendritic cell–surface protein DC-SIGN. To target dendritic cells, we enveloped the lentivector with a viral glycoprotein from Sindbis virus engineered to be DC-SIGN–specific. In vitro, this lentivector specifically transduced dendritic cells and induced dendritic cell maturation. A high frequency (up to 12%) of ovalbumin (OVA)-specific CD8+ T cells and a significant antibody response were observed 2 weeks after injection of a targeted lentiviral vector encoding an OVA transgene into naive mice. This approach also protected against the growth of OVA-expressing E.G7 tumors and induced regression of established tumors. Thus, lentiviral vectors targeting dendritic cells provide a simple method of producing effective immunity and may provide an alternative route for immunization with protein antigens.Keywords
This publication has 50 references indexed in Scilit:
- Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingNature Reviews Immunology, 2007
- Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeuticsGene Therapy, 2007
- Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic CellsPLoS Pathogens, 2007
- Targeting lentiviral vectors to specific cell types in vivoProceedings of the National Academy of Sciences, 2006
- Widely Divergent Biochemical Properties of the Complete Set of Mouse DC-SIGN-related ProteinsJournal of Biological Chemistry, 2006
- Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell ToleranceThe Journal of Experimental Medicine, 2002
- Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34+ cord blood-derived dendritic cellsGene Therapy, 2002
- Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigenGene Therapy, 2000
- Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cellsGene Therapy, 1997
- A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph.The Journal of Experimental Medicine, 1996